Immune System Diseases
UK Regulator Approves Pharming’s Joenja for Rare Immune Disorder APDS, Leveraging FDA Review
Joenja, leniolisib, APDS, MHRA approval, FDA review, rare immune disorder, Pharming
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease